<DOC>
	<DOCNO>NCT01527487</DOCNO>
	<brief_summary>The investigator propose randomize phase II study evaluate pCR toxicity profile combination eribulin/cyclophosphamide ( ErC ) docetaxel /cyclophosphamide ( TC ) neoadjuvant therapy locally advance HER2-negative breast cancer .</brief_summary>
	<brief_title>Trial Eribulin/Cyclophosphamide Docetaxel/Cyclophosphamide Neoadjuvant Therapy Locally Advanced HER2-Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Histologically confirm invasive adenocarcinoma breast . 2 . Primary palpable disease confine breast axilla physical examination ( clinical Stage II III disease ) . For patient without clinically suspicious axillary adenopathy , primary must &gt; 2 cm diameter physical examination image study ( clinical T23 , N02 , M0 ) . For patient clinically suspicious axillary adenopathy , primary breast tumor size ( clinical T13 , N12 , M0 ) . Patients axillary node dissection pN3a ( i.e . ≥10 involve axillary node ) also eligible . 3 . Patients enter trial undergo axillary node dissection eligible meet entry criterion . 4 . Estrogen receptor ( ER ) progesterone receptor ( PR ) status primary tumor know pending time study registration . 5 . Resolution acute effect surgical procedure ≤ grade 1 . For patient , sentinel node and/or axillary node dissection , completion least 1 week prior initiation study treatment wellhealed wound require . 6 . Bilateral , synchronous breast cancer allow primary tumor HER2negative least one meet specify qualify tumor nodal inclusion criterion . 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) score 02 . 8 . Patients enter study must willing provide release tumor tissue collect baseline diagnostic procedure available , time future surgical procedure ( ) correlative test . If tissue available , patient still eligible enrollment study . 9 . No evidence metastatic disease , document complete stag workup ≤8 week prior initiation study treatment . 10 . No prior treatment breast cancer exception criterion # 3 . 11 . HER2negative tumor status define : Immunohistochemical ( IHC ) 01+ IHC 2+ IHC 3+ confirm FISH ( Fluorescence situ hybridization ) SISH ( Silver situ hybridization ) negative ( define ratio &lt; 2.2 ) 12 . Adequate hematologic function define : Absolute neutrophil count ( ANC ) ≥1500/μL Hemoglobin ( Hgb ) ≥10 g/dL Platelets ≥100,000/uL 13 . Adequate liver function define : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 x upper limit normal ( ULN ) Total bilirubin ≤ institutional ULN 14 . Adequate renal function define : Serum creatinine ≤1.5 mg/dL x ULN OR calculate creatinine clearance ≥50 mL/min CockcroftGault method : GRF = ( 140age ) x ( weight/kg ) x ( 0.85 female ) ( 72 x serum creatinine mg/dL ) 15 . Other laboratory testing : Serum magnesium ≥ institutional low limit normal ( LLN ) Serum potassium ≥the institutional LLN 16 . Female ≥18 year age . 17 . Negative serum pregnancy test within &lt; 7 day prior initial trial treatment . 18 . Female patient childbearing potential , female patient childbearing potential agree use adequate contraceptive measure approve study physician receive study treatment continue 3 week last dose study drug treatment , breastfeeding , negative serum pregnancy test prior start dose . 19 . Willingness ability comply trial followup procedure . 20 . Ability understand nature trial give write informed consent . 1 . Clinical T4 lesion , include inflammatory breast cancer . Clinical N3 involvement ( e.g. , ipsilateral , infraclavicular , supraclavicular , internal mammary node ) . 2 . Peripheral neuropathy ( motor sensory ) &gt; grade 1 accord Common Terminology Criteria Adverse Events version 4.0 ( CTCAE v4.0 ) . 3 . Patient receive radiotherapy treatment previous cancer include ≥30 % major bone marrow contain area ( e.g. , pelvis , lumbar , spine ) . 4 . Known suspected allergy hypersensitivity study drug ( i.e. , eribulin , cyclophosphamide , docetaxel ) know hypersensitivity polysorbate 80 . 5 . Patients acute chronic liver renal disease pancreatitis . 6 . Known diagnosis human immunodeficiency virus ( HIV ) , Hepatitis B ( HBV ) Hepatitis C ( HCV ) . 7 . Concurrent treatment ovarian hormonal replacement therapy hormonal agent raloxifene , tamoxifen selective estrogen receptor modulator ( SERM ) . Patients must discontinue use agent prior begin study treatment . However , use GNRH agonist purpose fertility preservation suppression heavy menses permit ( see Section 5.4.1 ) . 8 . Patient follow cardiac disease currently within last 6 month : Left Ventricular Ejection Fraction ( LVEF ) &lt; 45 % determined Multiple Gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) Heart ratecorrected QT interval ( QTc ) &gt; 480 m screen electrocardiogram ( ECG ) ( use Bazett 's formula ) Unstable angina pectoris Congestive heart failure ( New York Heart Association [ NYHA ] ≥ Grade 2 Acute myocardial infarction Conduction abnormality control pacemaker medication Significant ventricular supraventricular arrhythmia ( Patients chronic ratecontrolled atrial fibrillation absence cardiac abnormality eligible ) . Valvular disease significant compromise cardiac function 9 . Chronic use drug cause QTc prolongation . Patients must discontinue use drug 7 day prior start study treatment . 10 . Presence active cancer , history treatment invasive cancer ≤5 year . Patients stage I cancer receive definitive local treatment least 3 year previously , consider unlikely recur eligible . All patient previously treat situ carcinoma ( i.e . noninvasive ) eligible , patient history nonmelanoma skin cancer . 11 . Patients may receive investigational anticancer treatment participate trial . 12 . Psychological , familial , sociological , geographical condition permit compliance protocol . 13 . Inability unwillingness comply study and/or followup procedure outline protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>eribulin</keyword>
	<keyword>Halaven</keyword>
	<keyword>taxotere</keyword>
</DOC>